Jeff Aronin is an American biopharmaceutical CEO and entrepreneur. He is the chief executive officer and chairman of Paragon Biosciences, a company that incubates and invests in innovative biotech startups.
Aronin’s interest in pharmaceutical biotechnology began when he was following and observing a physician treating a patient who was having repeated seizures due to epilepsy. Instead of solving the illness the traditional way by performing a complex surgical procedure, the physician thought of another way to control the seizures and gave the patient a drug that effectively reduced the seizures instead. That decision, and the need for more medicines like the one used for that patient, drove Jeff Aronin toward a career dedicated to helping patients live better.
Paragon Biosciences is a focuses on the life sciences industry. It invests in, develops, and accelerates the progress of companies that create major advancements in biotechnology and enhance patient care. The companies Paragon Biosciences has helped grow all concentrate on finding solutions to debilitating diseases. Paragon’s team has successfully launched 13 new drugs over the past decade (http://www.worldbusinesschicago.com/profile/jeff-aronin/).
Aside from the management of Paragon Biosciences, Jeff Aronin also works with the World Business Chicago Board of Directors and is the co-chairman of MATTER—an incubator community of healthcare innovators in Chicago. The CEC recognized Jeff Aronin’s contribution in the establishment of MATTER and awarded him the Entrepreneurial Champion Award in 2015.
Jeff Aronin received his bachelor’s of science degree from Northern Illinois University and finished his master’s in business administration degree at DePaul University. He is also a Fellow with the Aspen Institute (Jeffaronin). Outside the office, he is a frequent lecturer at the Northwestern University’s Kellogg School of Management and the University of Chicago Booth School of Business.